Diazepam
FDA-approved product (tablet, oral), marketed as Diastat, Diastat Acudial, Diazepam and 6 more.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Agitation
- Anxiety
- Anxiety disorder
- Cerebral palsy
- Epilepsy
- Stiff-Person syndrome
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Benzodiazepine derivatives
- FDA pharmacologic class
- Benzodiazepine FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA49.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli27.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae17.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis57.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Diazepam with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Mefloquine HydrochlorideExisting use: Malaria, Plasmodium falciparum malaria, Plasmodium vivax malaria81.8% AI-predicted activityagainst M. tuberculosisLab records exist8 registered studies
- KetoconazoleExisting use: Adrenal gland disease, Blastomycosis, Cushing syndrome and 3 more81.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- LevoketoconazoleExisting use: Adrenal gland disease, Adrenal gland hyperfunction, Cushing syndrome81.2% AI-predicted activityagainst M. tuberculosis6 registered studies
- Fluphenazine DecanoateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosis4 registered studies
- Fluphenazine EnanthateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- NifurtimoxExisting use: American trypanosomiasis, Chagas disease, Leishmaniasis and 1 more78.4% AI-predicted activityagainst M. tuberculosis19 registered studies
- Fluphenazine HydrochlorideExisting use: Mental or behavioural disorder, Psychosis77.8% AI-predicted activityagainst M. tuberculosis5 registered studies
- NitazoxanideExisting use: Amebiasis, Diarrhea77.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TopiramateExisting use: Epilepsy, Lennox-Gastaut syndrome, Migraine disorder and 1 more77.4% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TrabectedinExisting use: Cancer, Dedifferentiated liposarcoma, Leiomyosarcoma and 7 more76.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Chlorpromazine HydrochlorideExisting use: Conduct disorder, Mental or behavioural disorder, Nausea and vomiting and 3 more75.0% AI-predicted activityagainst M. tuberculosis33 registered studies
- ProchlorperazineExisting use: Anxiety disorder, Nausea and vomiting, Psychosis and 1 more74.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Treating Benign Paroxysmal Positional Vertigo (BPPV) in ED Patients
NCT00641797 · start 2006-11
Registered record
- Registry ID
- NCT00641797
- Conditions
- Benign Paroxysmal Positional Vertigo
- Interventions
- Meclizine; Epley Maneuver; Lorazepam; Diphenhydramine; Ondansetron
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2006-11
- Completion
- 2013-11
- Enrolment
- 26
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBenign Paroxysmal Positional VertigoInterventionMeclizine; Epley Maneuver; Lorazepam; Diphenhydramine +1 morePhaseNot applicableRegistry statusCompletedIntranasal Midazolam Versus Rectal Diazepam for Treatment of Seizures
NCT00326612 · start 2006-06
Registered record
- Registry ID
- NCT00326612
- Conditions
- Seizures
- Interventions
- Midazolam; Diazepam
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2006-06
- Completion
- 2008-12
- Enrolment
- 358
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSeizuresInterventionMidazolam; DiazepamPhasePhase 2Registry statusCompletedExcessive Crying in Children With Cerebral Palsy and Communication Deficits
NCT04523935 · start 2005-12-07
Registered record
- Registry ID
- NCT04523935
- Conditions
- Cerebral Palsy; Excessive Crying; Pain
- Interventions
- Placebo; Baclofen, Diazepam, Clonazepam, Trihexyphenidyl, Tetrabenazine, Gabapentin, Topiramate, Lamotrigine, Amitriptyline.
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2005-12-07
- Completion
- 2020-08-04
- Enrolment
- 131
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCerebral Palsy; Excessive Crying; PainInterventionPlacebo; Baclofen, Diazepam, Clonazepam, Trihexyphenidyl, Tetrabenazine, Gabapentin, Topiramate, Lamotrigine, Amitriptyline.PhasePhase 4Registry statusCompletedComparison Between Nurse-Administered Propofol Sedation and Diazemuls / Pethidine in Outpatient Colonoscopy
NCT00566683 · start 2005-07
Registered record
- Registry ID
- NCT00566683
- Conditions
- Colonoscopy
- Interventions
- diazemuls, pethidine; Propofol and Alfentanil
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2005-07
- Completion
- 2006-06
- Enrolment
- 194
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionColonoscopyInterventiondiazemuls, pethidine; Propofol and AlfentanilPhaseNot applicableRegistry statusCompletedThe Effect of Valproate on Benzodiazepine Withdrawal Severity
NCT00570219 · start 2005-02
Registered record
- Registry ID
- NCT00570219
- Conditions
- Substance Withdrawal Syndrome
- Interventions
- valproate
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2005-02
- Completion
- 2008-05
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSubstance Withdrawal SyndromeInterventionvalproatePhaseNot applicableRegistry statusCompleted